Three major Indian companies have made significant announcements across steel production, pharmaceutical compliance, and artificial intelligence partnerships, highlighting diverse developments in the corporate sector.

Tata Steel Achieves Strong Production Growth

Tata Steel Limited has reported robust operational performance with consolidated output reaching 8.33 million tonnes in the December quarter, marking an 8% increase from 7.71 million tonnes recorded in the corresponding period of the previous year.

| Production Metric: | December Quarter | Previous Year | Growth || | ---: | :--- | :--- | :--- | | Consolidated Output: | 8.33 million tonnes | 7.71 million tonnes | 8% |

The production figures notably exclude contributions from the company's UK operations, where Tata Steel is currently constructing an electric arc furnace (EAF) based steel plant with capacity exceeding 3.2 million tonnes as part of its green transition strategy. During this transition period, Tata Steel UK continues serving customers through downstream processing of purchased substrate materials.

Infosys Announces Strategic AI Partnership

Infosys Limited, the global digital services and consulting leader, has entered into a strategic collaboration with Cognition, the company behind Devin, recognized as the first AI software engineer. This partnership aims to scale Devin's capabilities across global enterprises and integrate advanced AI solutions into business operations.

The collaboration encompasses several key components:

• Deployment of Devin across Infosys' internal engineering ecosystem
• Integration into client engagements worldwide
• Utilization of Infosys Topaz Fabric, a purpose-built agentic services suite
• Creation of a multi-layer AI fabric unifying infrastructure, models, data, applications, and workflows

The collaboration combines Infosys Topaz Fabric's secure, modular architecture with Cognition's advanced agentic and autonomous engineering capabilities. The partnership targets accelerated time-to-market, enhanced developer productivity, and reduced modernisation timelines for enterprises.

Cipla Addresses FDA-Related Media Reports

Cipla Limited has issued clarifications regarding media reports concerning inspectional observations from the US Food and Drug Administration related to its supply partner Pharmathen International SA. The pharmaceutical company received communication from stock exchanges requesting clarification on reports about FDA inspectional observations recorded in Form 483.

These corporate developments reflect ongoing operational excellence, technological advancement, and regulatory compliance efforts across different sectors of the Indian business landscape.

Global and domestic brokerages have issued fresh recommendations on multiple Indian companies ahead of Tuesday's trading session, covering sectors from healthcare and consumer staples to travel and financial services. The updated views reflect evolving market conditions and company-specific developments across various industries.

Healthcare Sector Outlook

Citi has maintained its positive stance on Apollo Hospitals, upgrading the target price to ₹9,600 from ₹9,330 while retaining a Buy rating. The brokerage believes near-term challenges are largely priced into the stock, improving the risk-reward proposition.

The hospital chain faces headwinds from losses in new hospitals and disruption in Bangladesh patient inflows. However, Citi expects the ramp-up in new facilities could drive over 100 basis points of margin expansion by FY28. The brokerage also noted that HealthCo is transitioning from a drag to a value creator as offline pharmacy scales.

Travel and Tourism Sector Updates

Jefferies has provided comprehensive updates across the travel ecosystem, maintaining Buy ratings while adjusting target prices based on sector dynamics. The brokerage sees resilience in 2026 despite current sector challenges.

Jefferies highlighted that airlines face capacity constraints due to new flight duty norms, while airports benefit from traffic recovery and retail scaling. The brokerage's sector preference order remains: Airports > Airlines > Hotels.

Consumer Staples and Discretionary

Britannia Industries received a significant upgrade from Jefferies, moving to Buy from Hold with a substantially raised target price of ₹7,300 from ₹6,350. The upgrade reflects expectations of improving conditions in 2026 following a challenging 2025 marked by muted demand and margin pressure.

Morgan Stanley maintained an Overweight rating on Titan Company with a target price of ₹4,062, following Q3 results that beat estimates with 40% jewellery revenue growth. The growth was driven by higher average selling prices rather than buyer additions, with buyer growth remaining flat during the quarter.

Energy and Industrial Sectors

Reliance Industries received continued support from Jefferies, which maintained a Buy rating while raising the target price to ₹1,830 from ₹1,785. The brokerage identified tariff hikes and Jio's potential listing as key catalysts for 2026.

Key Growth Drivers for Reliance Industries:

• Jio expected to be primary growth driver
• 13% consolidated EBITDA growth projected for FY27
• Retail growth recovery anticipated in FY27
• Additional optionality from FMCG, new energy and data centres

Banking and Financial Services

Nomura initiated coverage on IDFC First Bank with a Buy rating and target price of ₹105, citing the bank's entry into an operating leverage inflection phase. The brokerage expects strengthening earnings momentum with improving profitability and moderating credit costs as asset quality stress has been addressed.

Market Strategy and Outlook

Morgan Stanley's India Strategy team, led by Ridham Desai, presented an optimistic outlook for Indian equities. The brokerage expects positive earnings revisions ahead of consensus, supported by RBI policy measures and potential policy reforms including privatisation.

Strategic Preferences:

• Overweight: Financials, Consumer Discretionary, Industrials
• Underweight: Energy, Materials, Utilities, Healthcare
• Focus: Domestic cyclicals over defensives
• Key risks: Global slowdown, geopolitical escalation